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Targeted molecular therapy with the selective Bcr-Abl tyrosine
kinase inhibitor imatinib (STI571, Gleevec) has revolutionized
the treatment of chronic myeloid leukemia (CML) (Druker et al.,
1996, 2001).The clinical efficacy of imatinib can be attributed to
several factors: the critical role of the Bcr-Abl kinase in the
pathogenesis of CML, exceptional target specificity of imatinib
along with excellent pharmacokinetics, and a high level of toler-
ability. Conspicuously absent from this list is “extremely high
potency”—imatinib is a rather average inhibitor from the stand-
point of binding affinity (IC50: 300 nM versus wild-type Bcr-Abl).
Despite the clinical success of imatinib therapy, an important
question is raised: would an inhibitor combining the attributes of
imatinib with a substantially higher affinity for Bcr-Abl be more
effective as a therapeutic agent for CML? The identification and
characterization of just such an inhibitor, AMN107, are present-
ed in this issue of Cancer Cell by Weisberg et al. (2005). Their
data suggest that AMN107 may also find application in the
treatment of imatinib-resistant CML.
AMN107 (Figure 1) was developed using a rational drug
design strategy in which imatinib served as the lead com-
pound. The crystal structure of the Abl kinase domain in com-
plex with imatinib reveals that few changes to the inhibitor
structure are likely to be tolerated (Nagar et al., 2002;
Schindler et al., 2000). The drug fits into the canonical ATP
binding site lining the groove between the N and C lobes and
penetrates into the central region of the kinase. Thus, the close
match between the core of the inhibitor and its binding site pro-
hibits alterations within this region of imatinib. However, the
methylpiperazinyl group of imatinib lies along a partially
hydrophobic, surface-exposed pocket of the Abl kinase, and is
more amenable to modification. Methodical replacement of this
ring system led to the discovery of AMN107, a close relative of
imatinib with more than 20-fold improved affinity for wild-type
Bcr-Abl. As a testament to the Bcr-Abl-specific design require-
ments built into AMN107, the improvement in binding affinity
for Bcr-Abl is not carried through to Kit or PDGFR. Although
these kinases are inhibited by AMN107, their affinities for
AMN107 are very similar to those of imatinib. The relative rank-
ing of affinities with respect to imatinib is PDGFR > Kit > Bcr-
Abl, while the order for AMN107 is Bcr-Abl > PDGFR > Kit.
Thus, AMN107 is a more potent and more specific inhibitor of
the Abl kinase than imatinib.
Weisberg et al. initially established that AMN107 blocks pro-
liferation of cell lines expressing wild-type Bcr-Abl with ?20-fold
greater potency than imatinib. Results from a murine CML
model demonstrate that AMN107 prolongs survival of nude
mice injected with 32D cells expressing wild-type Bcr-Abl and of
mice transplanted with bone marrow infected with retrovirus
expressing Bcr-Abl. In all cases, treatment with AMN107 result-
ed in a significant reduction in the accumulation of leukemic
cells in the spleen, bone marrow, liver, and lymph nodes.
Although a more potent Bcr-Abl kinase inhibitor might be
better than imatinib for treating newly diagnosed patients with
chronic phase CML, the real push in the Bcr-Abl inhibitor field
has been to develop alternate inhibitors to treat imatinib-resis-
tant CML. Currently, >95% of newly diagnosed patients with
chronic phase disease achieve durable responses on imatinib
therapy. Relapses are observed in only a small percentage of
these patients, but are the rule for patients with advanced dis-
ease. The leading cause of acquired resistance to imatinib is
reactivation of Bcr-Abl kinase activity due to mutations in its
kinase domain that decrease its sensitivity to imatinib by 3- to
>100-fold (reviewed in Deininger et al., 2004). To date, at least
30 different mutations within the Bcr-Abl kinase domain have
been identified in patient samples (reviewed in Hochhaus and
La Rosée, 2004), and in vitro experiments confirm that these
mutations reduce imatinib sensitivity to a variable degree.
The crystal structure of Abl in complex with imatinib
revealed the structural basis by which kinase domain mutations
confer imatinib resistance (Nagar et al., 2002; Schindler et al.,
2000). Imatinib binds to a unique, inactive conformation of the
Abl kinase domain in which the activation loop is in a closed
position. Mutations that confer resistance to imatinib either
affect residues directly involved in drug binding, impair the abili-
ty of the kinase domain to undergo the extensive conformation-
al changes required for imatinib binding, or favor the active
conformation of the kinase to which imatinib is unable to bind.
As reported by Weisberg et al., AMN107 also binds to the
inactive conformation of the Abl kinase domain. Given the struc-
tural similarities between imatinib and AMN107, and because
most imatinib-resistant mutations occur in regions of the kinase
domain that contact the conserved portions of these two
inhibitors, it would be predicted that the differences in sensitivity
to imatinib of wild-type versus mutant Bcr-Abl would be pre-
served in AMN107. As shown, this is exactly the case, with most
of the mutants being approximately 20-fold more sensitive to
AMN107 than to imatinib (Figure 1). One exception to this is
T315I, which is completely insensitive to AMN107, presumably
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because this is a residue that makes a direct contact to
AMN107.The other exception is M351T, which is more sensitive
to AMN107 than would be predicted. This residue makes close
contact with imatinib, but not with AMN107, due to the differ-
ences in chemical structure between AMN107 and imatinib.
Therefore, M351T affects the binding of imatinib, but has little
effect on the binding of AMN107. Although several common
mutations, such as Y253F, F311L, M359V, and H396P/R were
not analyzed, it seems likely that similar results would be
obtained with these mutants. Regardless, the findings with the
mutants challenge the notion that imatinib is conformationally or
sterically excluded from the mutated Abl kinase domain, and
suggest that a drug with an improved grip may have even more
clinical utility than anticipated.
A comparison of IC50 values of imatinib and AMN107 for
blocking proliferation of Ba/F3 cells expressing wild-type Bcr-
Abl or imatinib-resistant mutants is illustrated in Figure 1 (based
on data presented in Weisberg et al., 2005). As seen in this fig-
ure, if AMN107 drug levels match or even approach those of
imatinib (the mean plasma trough concentration of imatinib at a
dose of 400 mg is ?1.5 µM  [Druker et al., 2001; Peng et al.,
2004]; dotted line in Figure 1), AMN107 would be predicted to
have excellent clinical potential as a therapeutic agent for ima-
tinib-refractory CML. At present, the safety, tolerability, and
pharmacokinetic profile of AMN107, which ultimately will deter-
mine its clinical utility, remain to be established.
Another drug that has attracted attention with respect to
imatinib-resistant CML is the dual Src/Abl inhibitor BMS-354825
(Deininger and Druker, 2004; Shah et al., 2004). This inhibitor,
which exhibits approximately 300-fold greater affinity than ima-
tinib for the Abl kinase, binds the kinase domain irrespective of
the conformation of the activation loop. In addition, BMS-
354825 makes fewer contacts with Abl than does imatinib or
AMN107, and places less stringent conformational require-
ments on the kinase. In contrast to ima-
tinib and AMN107, BMS-354825 is also
an inhibitor of Src kinases. BMS-354825
effectively inhibited all imatinib-resistant
Bcr-Abl mutants in vitro, except T315I,
and prolonged the survival of mice inject-
ed with wild-type Bcr-Abl or cells
expressing M351T mutant, which is mar-
ginally resistant to imatinib.
Both AMN107 and BMS-354825 fail
to inhibit the T315I mutant of Bcr-Abl.
Given the location of this residue in the
“gatekeeper” region of the ATP binding
site, this mutant may prove difficult to
inhibit with ATP mimetics. In contrast,
Bcr-Abl inhibitors that block the substrate
binding site rather than the ATP binding site might be capable of
inhibiting this mutant. A recent report profiling a non-ATP-com-
petitive inhibitor of Bcr-Abl, ON012380, demonstrates the
potential utility of this approach (Gumireddy et al., 2005).
Interestingly, ON012380 inhibits wild-type and all imatinib-resis-
tant kinase domain mutations tested, including T315I, with an
IC50 of 10 nM or less.
The key finding from the study of imatinib resistance is that
Bcr-Abl signaling remains central to disease pathogenesis,
implying that selective inhibition of wild-type and imatinib-resis-
tant Bcr-Abl signaling is still the therapeutic strategy of choice.
Thus, the discovery of potent, structurally, and mechanistically
distinct inhibitors of imatinib-resistant Bcr-Abl mutants repre-
sents a major advance.What is the best way to utilize these new
Bcr-Abl inhibitors? Preliminary data from the phase I trials of
AMN107 and BMS-354825 as single agents are encouraging
(Giles et al., 2004; Sawyers et al., 2004). ON012380 has not yet
entered clinical trials. Depending on the outcome of clinical tri-
als of these agents, one potentially powerful approach would be
to use these drugs in combination. The rationale for such an
approach is that an inhibitor cocktail may target the widest
range of resistant clones and thereby prohibit or delay the onset
of acquired drug resistance. In this regard, we have preliminary
data showing that the combination of imatinib and BMS-354825
have additive antiproliferative activities. However, combinations
would have to be evaluated for toxicity in clinical trials.
A second potential role for these more potent Bcr-Abl
inhibitors would be to target residual leukemia that persists in
patients in whom imatinib induces durable remissions but fails
to eradicate the disease. With imatinib, the majority of patients
achieve a 3-log reduction in leukemic burden, but few achieve
undetectable levels of Bcr-Abl transcripts. Although the precise
mechanisms underlying disease persistence remain to be eluci-
dated, it is conceivable that more complete suppression of Bcr-
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Figure 1. Comparison of imatinib and AMN107
IC50 values for blocking proliferation of Ba/F3
cells expressing wild-type Bcr-Abl or kinase
domain mutated Bcr-Abl
Solid gray bars indicate imatinib IC50 values, and
solid red bars indicate AMN107 IC50 values.
Dotted black line indicates the mean trough
plasma level of imatinib reported in patients 24
hr following treatment with a once-daily dose of
400 mg. The figure is based on data presented
in Weisberg et al. (2005).
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Abl kinase with a high potency inhibitor or a combination of
inhibitors may be able to target the cell population responsible
for disease persistence.
AMN107, BMS-354825, and ON012380 have many more
hurdles to clear before taking a place alongside imatinib, or
even someday replacing it as a frontline CML therapeutic agent.
However, the findings of Weisberg et al. (2005), Shah et al.
(2004), and Gumireddy et al. (2005) are extremely encouraging
and represent good news for patients with CML. Perhaps most
remarkable is how quickly an understanding of the mechanism
of imatinib resistance has translated into new treatments,
demonstrating the speed at which drug development can occur.
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